Results 61 to 70 of about 30,354 (250)

Low-density lipoprotein receptor genotypes modify the sera metabolome of patients with homozygous familial hypercholesterolemia

iScience, 2022
Summary Homozygous familial hypercholesterolemia (HoFH) is an extremely rare metabolism disorder usually caused by low-density lipoprotein receptor (LDLR) mutations.
Zhiyong Du, Fan Li, Linyi Li, Yu Wang, Jianping Li, Ya Yang, Long Jiang, Luya Wang, Yanwen Qin   +8 more
semanticscholar   +1 more source

Apolipoprotein B metabolism in homozygous familial hypercholesterolemia.

Journal of Lipid Research, 1989
This report describes the metabolism of apolipoprotein B-containing lipoproteins in seven familial hypercholesterolemic (FH) homozygotes and compares the results to the values obtained from five healthy control subjects.
R W James, B Martin, D Pometta, J C Fruchart, P Duriez, P Puchois, J P Farriaux, A Tacquet, T Demant, R J Clegg   +9 more
doaj   +1 more source

Quality of life and coping in Dutch homozygous familial hypercholesterolemia patients: A qualitative study.

Atherosclerosis, 2022
BACKGROUND AND AIMS Homozygous familial hypercholesterolemia (HoFH) is characterized by severely elevated low-density lipoprotein cholesterol (LDL-C) levels leading to extremely premature atherosclerotic cardiovascular disease.
J. Mulder, L. Kranenburg, W. J. Treling, G. Hovingh, J. Rutten, J. Busschbach, J. E. Roeters van Lennep   +6 more
semanticscholar   +1 more source

A Case Report of Homozygous Familial Hypercholesterolemia Liver Transplantation

罕见病研究, 2023
Homozygous familial hypercholesterolemia (HoFH) is a rare and serious autosomal genetic metabolic disease. Patients without intervention often die younger than 30 years old from early atherosclerotic cardiovascular disease (ASCVD)incurred by extremely ...
CHEN Peipei, TIAN Zhuang, CHEN Wei, MA Mingsheng, LIU Xin, QIN Yan, XU Haifeng, ZHU Zhijun, ZHANG Shuyang   +8 more
doaj   +1 more source

Current treatments for the management of homozygous familial hypercholesterolemia: a systematic review and commentary.

European Journal of Preventive Cardiology
AIMS Homozygous familial hypercholesterolemia (HoFH) is a rare disorder characterized by markedly elevated circulating low-density lipoprotein cholesterol (LDL-C) from birth.
Jing Gu, R. N. Gupta, Henry Cheng, Yingxin Xu, F. Raal   +4 more
semanticscholar   +1 more source

Efficacy and Safety of Alirocumab in Adults With Homozygous Familial Hypercholesterolemia: The ODYSSEY HoFH Trial.

Journal of the American College of Cardiology, 2020
BACKGROUND Homozygous familial hypercholesterolemia (HoFH) is characterized by extremely elevated low-density lipoprotein-cholesterol (LDL-C) levels and early onset atherosclerotic cardiovascular disease despite treatment with conventional lipid-lowering
D. Blom, M. Harada‐Shiba, P. Rubba, D. Gaudet, J. Kastelein, M. Charng, R. Pordy, S. Donahue, Shazia Ali, Yuping Dong, N. Khilla, P. Banerjee, M. Baccara-Dinet, R. Rosenson   +13 more
semanticscholar   +1 more source

Homozygous familial hypercholesterolemia: A rare case report

Indian Journal of Paediatric Dermatology, 2018
A 9-year-old male child presented with asymptomatic skin-colored-to-yellowish nodules over both the buttocks, feet, and over the right Achilles' tendon for 4 years.
Shashikant Malkud, Sirisha Varala, Geeta Kiran Arakkal, Purnachandra Badabagni   +3 more
doaj   +1 more source

Sex Differences in Diagnosis, Treatment, and Cardiovascular Outcomes in Homozygous Familial Hypercholesterolemia.

JAMA Cardiol
Importance Homozygous familial hypercholesterolemia (HoFH) is a rare genetic condition characterized by extremely increased low-density lipoprotein (LDL) cholesterol levels and premature atherosclerotic cardiovascular disease (ASCVD).
Mulder JWCM, Tromp TR, Al-Khnifsawi M, Blom DJ, Chlebus K, Cuchel M, D'Erasmo L, Gallo A, Hovingh GK, Kim NT, Long J, Raal FJ, Schonck WAM, Soran H, Truong TH, Boersma E, Roeters van Lennep JE, Homozygous Familial Hypercholesterolemia International Clinical Collaborators.   +17 more
europepmc   +2 more sources

Ezetimibe therapy: mechanism of action and clinical update. [PDF]

, 2012
The lowering of low-density lipoprotein cholesterol (LDL-C) is the primary target of therapy in the primary and secondary prevention of cardiovascular events.
Dayspring, Thomas D, Phan, Binh An P, Toth, Peter P   +2 more
core   +1 more source

Complementary role of evinacumab in combination with lipoprotein apheresis in patients with homozygous familial hypercholesterolemia

Therapeutic apheresis and dialysis, 2022
Patients with homozygous familial hypercholesterolemia (FH) have severe hypercholesterolemia from birth and if untreated may experience very early onset of coronary artery disease in childhood or young adulthood with an aggressive course resulting in ...
P. Duell, B. Warden
semanticscholar   +1 more source